OakChart

ORIC Pharmaceuticals Inc

ORICHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:52 AM ET

8.92+0.01 (0.17%)
2026-11-11 16:52 CET
Market cap
923.55 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-140.35 USD m
Free cash flow, TTM
-114.99 USD m
EPS diluted, TTM
-1.35
P/E
-
Compare

Price

ORIC against its 20, 50 and 200-day averages
2050200miss
8.0010.0012.0014.003.5M7.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ORICclose 8.9320-day 10.5150-day 11.74200-day 11.028.9352w high52w low

39.2% under the 52-week high of 14.68 on 19 Aug 2026. 52-week low 7.23 on 2 Apr 2026. Last 15 sessions, 70.9% high to low

Profile

ORIC
52-week range, 23% of the way up
7.2314.68

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

IndexRUT
Employees104
IPOApr 24, 2020
Beta1.22
ATR, 14d0.85
Rel volume0.20
Short float15.73%
Insider own34.19%
Inst own86.35%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap925.09M
Enterprise Value663.66M
Income-140.35M
Sales0.00M
Book/sh3.68
Cash/sh2.55
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees104
IPOApr 24, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.43
P/C3.49
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio13.19
Current Ratio13.19
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.35
EPS next Y-1.67
EPS next Q-0.39
EPS this Y-2.44%
EPS next Y-11.12%
EPS next 5Y-7.08%
EPS past 3/5Y13.10% 15.18%
Sales past 3/5Y- -
EPS Y/Y TTM28.64%
Sales Y/Y TTM-
EPS Q/Q17.45%
Sales Q/Q-
EarningsAug 03 AMC
EPS/Sales Surpr.-5.76% -

Ownership

Insider Own34.19%
Insider Trans-0.35%
Inst Own86.35%
Inst Trans4.77%
ROA-37.35%
ROE-39.80%
ROIC-36.81%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-15.05%
SMA50-24.00%
SMA200-19.03%
Trades-

Technical

Shs Outstand103.64M
Shs Float68.21M
Short Float15.73%
Short Ratio6.90
Short Interest10.73M
52W High14.68 -39.20%
52W Low7.23 23.44%
Volatility8.47% 10.00%
ATR (14)0.85
RSI (14)36.91
Beta1.22
Rel Volume0.20
Avg Volume1.56M
Volume77,414

Performance

Perf Week-4.44%
Perf Month-21.09%
Perf Quarter-34.95%
Perf Half Y3.78%
Perf YTD9.11%
Perf Year-30.71%
Perf 3Y43.03%
Perf 5Y-49.66%
Perf 10Y-
Recom1.12
Target Price21.71
Prev Close8.91
Price8.92
Change %0.17%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 05, 2026InitiatedLLeerink PartnersOutperform$26+191.3%
Sep 23, 2026InitiatedBBTIG ResearchBuy$26+191.3%
Jun 12, 2026ResumedSStifelBuy$14+56.9%
May 15, 2026UpgradeGGoldmanNeutral → Buy$15+68.1%
Jan 07, 2026InitiatedPPiper SandlerOverweight$22+146.5%
Nov 20, 2025InitiatedEEvercore ISIOutperform$25+180.1%
Nov 18, 2025InitiatedWWolfe ResearchPeer Perform
Sep 04, 2025ResumedGGuggenheimBuy$18+101.7%
Jul 08, 2025InitiatedLLadenburg ThalmannBuy$15+68.1%
Oct 31, 2024InitiatedWWells FargoOverweight$20+124.1%

Peers

Mkt cap
TickerCompanyMkt cap
CGEMCullinan Therapeutics Inc727.53M
JANXJanux Therapeutics Inc746.29M
ARVNArvinas Inc444.28M
BDTXBlack Diamond Therapeutics Inc91.64M
NUVBNuvation Bio Inc1.53B
IDYAIdeaya Biosciences Inc3.13B
TYRATyra Biosciences Inc1.44B
ERASErasca Inc5.87B
RLAYRelay Therapeutics Inc4.41B
TNGXTango Therapeutics Inc4.28B

Insider trading

latest 14 of 38
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Piscitelli DominicChief Financial OfficerOct 20 '26Option Exercise4.3614,00061,04083,828Oct 21 05:17 PM
Piscitelli DominicChief Financial OfficerOct 20 '26Sale13.5314,000189,39169,828Oct 21 05:17 PM
Heyman Richard A.DirectorOct 01 '26Option Exercise1.603,5005,60041,800Oct 02 05:50 PM
Heyman Richard A.DirectorOct 01 '26Sale12.913,50045,19938,300Oct 02 05:50 PM
Heyman Richard A.DirectorOct 01 '26Sale12.913,20041,325203,472Oct 02 05:50 PM
Richard A, HeymanDirectorOct 01 '26Proposed Sale13.478,100109,107Oct 01 04:23 PM
Richard A, HeymanDirectorOct 01 '26Proposed Sale13.477,600102,372Oct 01 04:23 PM
Piscitelli DominicChief Financial OfficerSep 28 '26Option Exercise4.3613,40058,42483,228Sep 29 07:16 PM
Piscitelli DominicChief Financial OfficerSep 28 '26Sale13.5313,400181,25869,828Sep 29 07:16 PM
Piscitelli DominicChief Financial OfficerSep 24 '26Option Exercise4.366002,61670,428Sep 25 07:59 PM
Piscitelli DominicChief Financial OfficerSep 24 '26Sale13.506008,10269,828Sep 25 07:59 PM
Piscitelli DominicChief Financial OfficerAug 26 '26Option Exercise4.8977,000376,720146,828Aug 28 04:11 PM
Piscitelli DominicChief Financial OfficerAug 26 '26Sale13.6977,0001,053,81469,828Aug 28 04:11 PM
Dominic PiscitelliOfficerAug 26 '26Proposed Sale13.50229,5003,098,250Aug 26 04:09 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B

News

latest 14 of 206
  • ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.73%
  • ORIC Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 (GlobeNewswire)
  • ORIC Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial (GlobeNewswire)
  • ORIC Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 (GlobeNewswire)
  • Loading…
  • ORIC Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development (GlobeNewswire)
  • ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • ORIC Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates (GlobeNewswire) +27.08%
  • ORIC Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire)
  • ORIC Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA (Darolutamide), Supported by Clinical Collaboration with Bayer (GlobeNewswire) +5.59%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-03-0.380-0.359-0.3800.000.0015
2026Q12026-05-04-0.340-0.321-0.3390.000.0016
2025Q42026-02-24-0.300-0.340-0.2970.000.0015
2025Q32025-11-13-0.330-0.405-0.3290.000.0012
2025Q22025-08-12-0.470-0.443-0.4650.000.0010
2025Q12025-05-05-0.420-0.511-0.4230.000.009
2024Q42025-02-18-0.510-0.500-0.5140.000.0011
2024Q32024-11-12-0.490-0.478-0.4900.000.0012
2024Q22024-08-12-0.450-0.412-0.4540.000.009
2024Q12024-05-06-0.370-0.429-0.3710.000.009
2023Q42024-03-11-0.490-0.478-0.4930.000.009
2023Q32023-11-06-0.440-0.462-0.4440.000.008
2023Q22023-08-10-0.500-0.569-0.5030.000.007
2023Q12023-05-08-0.530-0.540-0.5310.000.006
2022Q42023-03-16-0.520-0.548-0.5190.000.006
2022Q32022-11-07-0.630-0.553-0.6270.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.470--0.8990.00-
2020FY-3.360-2.948-3.3590.000.00
2021FY-2.070-2.061-2.0740.000.00
2022FY-2.250-2.239-2.2470.000.00
2023FY-1.960-1.956-1.9570.000.00
2024FY-1.830-1.852-1.8340.000.00
2025FY-1.470-1.517-1.4700.000.00
2026FY--1.506--0.00
2027FY--1.673--0.00
2028FY--1.805--4.60
2029FY--2.024--49.10
2030FY--0.850--268.74

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-1311000.000.000.00
2026Q3S2026-10-0210000.000.000.00
2026Q3S2026-09-229000.000.000.00
2026Q3S2026-09-168000.000.000.00
2026Q3S2026-09-037000.000.000.00
2026Q3S2026-08-048000.000.000.00
2026Q3S2026-08-038000.000.000.00
2026Q3S2026-07-218000.000.000.00
2026Q3S2026-06-109000.000.000.00
2026Q3S2026-05-058000.000.000.00
2026Q3S2026-03-158000.000.000.00
2026Q3S2026-02-249000.000.000.00
2026Q3S2026-02-239000.000.000.00
2026Q3S2026-02-208000.000.000.00

Estimate history

EPS, annual-0.737-0.714-0.899-3.359-2.074-2.247-1.957-1.834-1.475-1.3499
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.454-0.49-0.514-0.423-0.465-0.329-0.297-0.339-0.384
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual29.90329.90329.90336.67239.4345.0954.86671.02298.529103.636
Period201720182019202020212022202320242025MRQ
Shares, quarterly67.67270.55971.02271.07986.18797.27898.529103.486103.636
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.141.221.111.030.970.900.971.000.90
Gross Profit-1.14-1.22-1.11-1.03-0.97-0.90-0.97-1.00-0.90
Selling, General and Administrative Excl. Other155.00141.78141.79109.7585.8077.9748.3727.5721.47
Research and Development122.36109.82114.0785.1761.6856.8635.9222.8419.03
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-156.14-143.00-142.90-110.78-86.77-78.87-49.34-28.57-22.37
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.005.000.0024.84--
Net Income Before Taxes-140.35-129.47-127.85-100.70-89.12-78.72-73.70-26.88-21.36
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-140.35-129.47-127.85-100.70-89.12-78.72-73.70-26.88-21.36
Net Income From Continuing Operations-140.35-129.47-127.85-100.70-89.12-78.72-73.70-26.88-21.36
Net Income-140.35-129.47-127.85-100.70-89.12-78.72-73.70-26.88-21.36
EPS (Recurring)-1.30-1.47-1.83-1.96-2.16-2.07-2.57-0.90-0.71
EPS (Basic, Before Extraordinaries)-1.35-1.47-1.83-1.96-2.25-2.07-3.36-0.90-0.71
EPS (Diluted)-1.35-1.47-1.83-1.96-2.25-2.07-3.36-0.90-0.71
EBITDA-155.00-141.78-141.79-109.75-85.80-77.97-48.37-27.57-21.47
Non-Operating Income (Expense)15.7913.5415.0510.082.650.160.481.691.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense25.9025.0420.2115.2314.4612.855.281.090.47
Shares Outstanding103.6498.5371.0254.8745.0939.4336.6729.9029.90
Market Capitalization923.55923.55569.48501.87233.11578.911,214.461,315.64-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.260.270.320.290.310.300.300.27
Gross Profit-0.26-0.27-0.32-0.29-0.31-0.30-0.30-0.27
Selling, General and Administrative Excl. Other45.0339.3534.2336.3838.7532.4239.2738.05
Research and Development36.3031.4425.8628.7730.5524.6431.9731.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-45.30-39.62-34.55-36.67-39.06-32.72-39.57-38.32
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-41.49-35.77-30.50-32.59-36.35-30.02-36.31-34.57
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-41.49-35.77-30.50-32.59-36.35-30.02-36.31-34.57
Net Income From Continuing Operations-41.49-35.77-30.50-32.59-36.35-30.02-36.31-34.57
Net Income-41.49-35.77-30.50-32.59-36.35-30.02-36.31-34.57
EPS (Recurring)-0.38-0.34-0.30-0.33-0.47-0.42-0.51-0.49
EPS (Basic, Before Extraordinaries)-0.38-0.34-0.30-0.33-0.47-0.42-0.51-0.49
EPS (Diluted)-0.38-0.34-0.30-0.33-0.47-0.42-0.51-0.49
EBITDA-45.03-39.35-34.23-36.38-38.75-32.42-39.27-38.05
Non-Operating Income (Expense)3.803.854.054.082.712.703.263.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.096.906.285.636.576.555.205.06
Shares Outstanding103.64103.4998.5397.2886.1971.0871.0270.56
Market Capitalization923.551,271.54796.641,165.48865.03396.33569.48723.06

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments281.49255.96208.19206.27236.98293.6089.1642.6425.82
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets6.986.294.414.183.543.100.841.090.79
Total Current Assets288.47262.25212.60210.46240.52296.7090.0043.7226.61
Net Property, Plant & Equipment9.0711.3012.0114.2514.211.982.242.512.90
Total Investments and Advances111.250.4927.3422.4243.850.000.000.000.00
Deferred Tax Assets2.112.592.683.183.41----
Other Assets0.100.100.060.050.050.321.850.500.51
Total Assets411.00276.73254.69250.36302.06299.0094.0946.7330.02
Short Term Debt Incl. Current Port. of LT Debt3.333.182.752.661.930.000.000.000.00
Accounts Payable3.821.550.941.321.890.760.150.450.94
Other Current Liabilities13.2620.1116.7611.4111.348.245.202.151.67
Total Current Liabilities20.4224.8520.4615.3915.159.005.352.602.61
Long Term Debt4.116.177.469.4410.520.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities2.112.592.683.183.41----
Other Liabilities0.000.000.000.000.000.220.771.301.69
Total Liabilities26.6433.6130.6028.0129.089.226.123.894.30
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00178.06107.2769.34
Common Equity384.36243.12224.09222.35272.98289.78-90.08-64.43-43.61
Total Shareholders Equity384.36243.12224.09222.35272.98289.7887.9742.8425.73
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity384.36243.12224.09222.35272.98289.7887.9742.8425.73
Total Liabilities & Stockholders Equity411.00276.73254.69250.36302.06299.0094.0946.7330.02
Book Value Per Share3.903.424.084.936.927.90-3.01-2.15-1.46
Tangible Book Value Per Share3.903.424.084.936.927.90-3.01-2.15-1.46
Full-Time Employees10411510086786157--
Price to Book Ratio2.422.082.031.092.124.286.08--
Return on Assets-37.65-48.12-39.88-32.27-26.19-37.50-38.18-55.66-
Return on Equity-41.27-54.73-45.11-35.99-27.98-39.02-41.10-62.31-
Return on Invested Capital-33.33-51.28-43.49-38.45-27.77-25.43-30.56-49.87-85.63
Quick Ratio14.1310.5610.3913.6815.8732.9616.8116.8410.20
Current Ratio14.1310.5610.3913.6815.8732.9616.8116.8410.20

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-140.35-129.47-127.85-100.70-89.12-78.72-73.70-26.88-21.36
Depreciation1.141.221.111.030.970.900.971.030.90
Other Funds (Non Cash)22.7920.3411.948.8513.0612.3525.421.000.48
Funds from Operations-116.42-107.91-114.80-90.81-75.10-65.47-47.31-24.85-19.98
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.05-5.461.974.90-0.454.072.041.22-0.71
Cash from Operating Activities-114.37-113.37-112.83-85.92-75.54-61.39-45.27-23.63-20.68
Capital Expenditures-0.62-0.71-1.19-0.85-2.08-0.94-0.67-0.77-0.53
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-99.04-147.3223.32-42.55-107.17159.37-215.490.000.00
Purchase of Investments-336.54-399.82-251.92-239.24-238.12-69.63-225.490.000.00
Sale Or Maturity of Investments237.50252.50275.25196.69130.95229.0010.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.190.000.02
Cash from Investing Activities-99.66-148.0322.14-43.40-109.25158.44-215.96-0.77-0.51
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock175.65247.66126.7285.8925.6250.99250.5170.9238.01
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock175.65247.66126.7285.8925.6250.99250.5170.9238.01
Proceedsfrom Stock Options307.24245.68126.0885.8325.5550.00250.0770.9238.01
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities175.65247.66126.7285.8925.6250.99250.5170.9238.01
Net Change in Cash-38.38-13.7436.02-43.43-159.17148.03-10.7146.5216.82
Free Cash Flow-114.99-114.08-114.02-86.76-77.62-62.33-45.94-24.40-21.21
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments264.76281.93281.49287.14282.51203.72
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets8.938.306.988.458.617.71
Total Current Assets273.69290.23288.47295.59291.12211.43
Net Property, Plant & Equipment2.242.159.072.562.763.02
Total Investments and Advances123.29138.27111.25126.4045.7120.53
Deferred Tax Assets--2.11---
Other Assets5.466.110.106.647.267.87
Total Assets404.69436.76411.00431.19346.86242.86
Short Term Debt Incl. Current Port. of LT Debt3.333.303.333.303.273.21
Accounts Payable3.872.903.822.903.135.16
Other Current Liabilities13.5611.5813.2613.9811.659.24
Total Current Liabilities20.7617.7720.4220.1818.0517.62
Long Term Debt0.000.004.110.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--2.11---
Other Liabilities2.673.430.004.094.815.50
Total Liabilities23.4321.2026.6424.2722.8623.12
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity381.26415.56384.36406.92324.00219.74
Total Shareholders Equity381.26415.56384.36406.92324.00219.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity381.26415.56384.36406.92324.00219.74
Total Liabilities & Stockholders Equity404.69436.76411.00431.19346.86242.86
Book Value Per Share3.684.023.904.183.763.09
Tangible Book Value Per Share3.684.023.904.183.763.09
Full-Time Employees111-104106128-
Price to Book Ratio2.423.251.963.193.281.63
Return on Assets-37.35-39.79-37.65-36.90-40.62-44.76
Return on Equity-39.80-42.57-41.27-39.73-43.82-48.45
Return on Invested Capital-10.88-8.61-7.85-8.01-11.22-13.66
Quick Ratio13.1916.3314.1314.6516.1312.00
Current Ratio13.1916.3314.1314.6516.1312.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-41.49-35.77-30.50-32.59-36.35-30.02
Depreciation0.260.270.320.290.310.30
Other Funds (Non Cash)7.386.076.043.305.575.43
Funds from Operations-33.85-29.43-24.15-29.00-30.48-24.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.24-4.001.662.14-0.78-8.49
Cash from Operating Activities-31.61-33.43-22.48-26.85-31.26-32.77
Capital Expenditures-0.36-0.00-0.23-0.04-0.06-0.39
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments12.22-17.9717.21-110.50-76.8722.84
Purchase of Investments-47.78-77.97-45.29-165.50-124.37-64.66
Sale Or Maturity of Investments60.0060.0062.5055.0047.5087.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities11.86-17.9816.98-110.53-76.9322.45
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.8362.131.50111.19134.720.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.8362.131.50111.19134.720.25
Proceedsfrom Stock Options0.6860.88245.680.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.8362.131.50111.19134.720.25
Net Change in Cash-18.9110.73-4.00-26.2026.53-10.07
Free Cash Flow-31.96-33.43-22.71-26.89-31.32-33.16

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.73%10.7M68.2M1.58M
2026-10-1522.61%15.4M68.2M1.48M
2026-09-3023.92%16.3M68.2M1.51M
2026-09-1525.70%17.5M68.2M1.53M
2026-08-3125.33%17.3M68.2M1.67M
2026-08-1426.98%18.4M68.2M1.71M
2026-07-3134.71%21.8M62.8M1.67M
2026-07-1535.23%22.1M62.6M1.62M
2026-06-3035.32%22.1M62.6M1.95M
2026-06-1533.65%21.1M62.6M1.89M
2026-05-2935.78%21.9M61.3M1.83M
2026-05-1535.80%21.9M61.3M1.92M
2026-04-3036.60%22.0M60.1M1.88M
2026-04-1536.43%20.7M56.9M1.95M
2026-03-3133.98%19.3M56.9M1.66M
2026-03-1336.27%20.7M56.9M1.67M
2026-02-2738.28%21.8M56.9M1.58M
2026-02-1338.83%22.1M56.9M1.51M
2026-01-3039.96%21.6M54.2M1.49M
2026-01-1539.02%21.1M54.2M1.40M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call3.003.508.504.9021.7685.000.000.980-0.0150.001
call4.002.506.004.908.0502.000.000.974-0.0150.001
call5.001.806.506.459.5153.000.000.932-0.0300.002
call6.000.805.504.309.0481.000.000.894-0.0340.003
call7.000.304.900.008.2880.000.000.779-0.0660.004
call8.000.104.906.009.0264.000.000.695-0.1220.005
call9.000.004.900.789.6051020.000.699-0.1820.005
call10.000.002.000.594.2869060.000.568-0.1310.006
call11.000.004.901.004.77371.000.000.540-0.1480.006
call12.000.001.000.444.7261,0820.000.493-0.1470.006
call13.000.004.900.105.58147.000.000.505-0.1730.006
call14.000.004.900.505.9043,2730.000.493-0.1830.006
call15.000.004.900.056.19450.000.000.483-0.1920.006
call16.000.002.502.005.98515.000.000.443-0.1840.006
call17.000.004.901.006.6937.000.000.467-0.2060.006
call18.000.004.900.145.0602510.000.315-0.1390.005
call19.000.004.901.657.1141.000.000.455-0.2190.006
call20.000.004.902.007.30067.000.000.450-0.2240.006
call21.000.004.900.007.4770.000.000.446-0.2290.006
call22.000.004.900.157.6411060.000.442-0.2340.006
call23.000.004.902.007.7951.000.000.438-0.2380.006
call24.000.004.901.757.9411.000.000.435-0.2420.006
call25.000.004.902.528.0774.000.000.432-0.2460.006
put3.000.004.900.003.9470.000.00-0.020-0.0150.001
put4.000.000.050.134.14322.000.00-0.060-0.0380.002
put5.000.000.150.103.16854.000.00-0.080-0.0360.002
put6.000.000.200.203.79349.000.00-0.168-0.0730.004
put7.000.000.650.602.86076.000.00-0.221-0.0660.004
put8.000.002.000.504.48298.000.00-0.305-0.1210.005
put9.000.151.900.933.3362140.00-0.299-0.1820.005
put10.001.204.802.527.56483.002.00-0.433-0.1300.006
put11.000.404.901.236.30035.000.00-0.460-0.1470.006
put12.001.005.503.615.9749.000.00-0.479-0.1600.006
put13.001.706.504.106.3511640.00-0.495-0.1710.006
put14.002.657.503.856.68716.000.00-0.507-0.1810.006
put15.003.608.400.006.8000.000.00-0.517-0.1900.006
put16.004.609.506.807.2221.000.00-0.526-0.1970.006
put17.005.7010.500.007.4810.000.00-0.533-0.2050.006
put18.006.6011.509.057.7070.000.00-0.539-0.2110.006
put19.007.6012.500.007.8870.000.00-0.545-0.2160.006
put20.008.6013.500.008.1020.000.00-0.550-0.2220.006
put21.009.6014.509.808.2791.000.00-0.554-0.2270.006
put22.0010.6015.500.008.4200.000.00-0.558-0.2310.006
put23.0011.6016.5011.108.6031.000.00-0.562-0.2360.006
put24.0012.7017.500.008.7420.000.00-0.565-0.2390.006
put25.0013.6018.500.008.8910.000.00-0.568-0.2430.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-238-KCurrent report2026-10-23SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-30S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-308-KCurrent report2026-07-28SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-02-264Statement of changes in beneficial ownership of securities2026-02-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000275.92K3
2026-0900189.36K2
2026-08001.05M1
2026-0700161.06K3
2026-060000
2026-050000
2026-040000
2026-030000
2026-0200702.69K1
2026-010080.43K2
2025-1200496.62K3
2025-110000

Institutional holders

Manager% owned
Nextech Invest Ltd.6.92%
BlackRock, Inc.6.59%
EcoR1 Capital, LLC6.50%
PRICE T ROWE ASSOCIATES INC /MD/6.39%
VIKING GLOBAL INVESTORS LP4.95%
STATE STREET CORP4.73%
SR ONE CAPITAL MANAGEMENT, LP4.46%
Venrock Adviser, LLC4.17%
NEA Management Company, LLC3.98%
VANGUARD CAPITAL MANAGEMENT LLC3.82%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.15%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.82%
iShares Russell 2000 ETF1.88%
ACAP Strategic Fund1.79%
T. Rowe Price Health Sciences Fund, Inc.1.48%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.22%
T. Rowe Price New Horizons Fund, Inc.1.08%
Eventide Healthcare & Life Sciences Fund0.92%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
Fidelity Small Cap Index Fund0.79%

OakChart. ORIC. Cached 15 minutes.